Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib in Relapsed/Refractory CLL
NCT02340780Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Apr 2015
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buparlisib in chronic lymphocytic leukemia (CLL), sponsored by Canadian Cancer Trials Group. Started Apr 2015; status: completed.
02
Drugs
buparlisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02340780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340780.